SCHEMBL8075110

SCHEMBL8075110

CCc1cc2ccc(C(Cl)C(C)C)cc2[nH]c1=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.46
HIF1A Q16665 2/20 0.46
KDM4E B2RXH2 9/20 0.43
HSD17B10 Q99714 6/20 0.43
DAO P14920 1/20 0.41
TSHR P16473 3/20 0.40
CYP1A2 P05177 1/20 0.40
POLB P06746 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C19 P33261 1/20 0.40
PARP1 P09874 2/20 0.40
KCNH2 Q12809 2/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
HPGD P15428 5/20 0.39
MAPT P10636 2/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
TP53 P04637 1/20 0.39
ALOX15 P16050 1/20 0.39
RXFP1 Q9HBX9 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8071185 0.88 ALDH1A1 (0.48) ALDH1A1HIF1AKDM4EHSD17B10DAO
SCHEMBL25912136 0.85 EIF4A3 (0.53) ALDH1A1HIF1AKDM4EHSD17B10DAO
SCHEMBL8082859 0.84 ALDH1A1 (0.47) ALDH1A1HIF1AKDM4EHSD17B10DAO
SCHEMBL8076561 0.82 BRD4 (0.50) ALDH1A1HIF1AKDM4EHSD17B10DAO
SCHEMBL8073461 0.82 ALDH1A1 (0.48) ALDH1A1HIF1AKDM4EHSD17B10DAO
SCHEMBL8153967 0.82 ALDH1A1 (0.48) ALDH1A1HIF1AKDM4EHSD17B10DAO
SCHEMBL8144919 0.79 ALDH1A1 (0.45) ALDH1A1HIF1AKDM4EHSD17B10DAO
SCHEMBL10289297 0.76 KDM4E (0.44) ALDH1A1HIF1AKDM4EHSD17B10DAO
Hydrochloric Acid SCHEMBL31571005 0.73 PARP1 (0.42) ALDH1A1HIF1AKDM4EHSD17B10DAO
Bromide SCHEMBL31571064 0.73 PARP1 (0.42) ALDH1A1HIF1AKDM4EHSD17B10DAO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025101892-A1 POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORS AND USES THEREOF Astellas Engineered Small Molecules US, Incorporated (US) 2025-05-15 WO disclosed
US-8404713-B2 Quinolinone derivatives as PARP inhibitors JANSSEN PHARMACEUTICA NV (BE) 2013-03-26 US disclosed
US-8404713-B2 Quinolinone derivatives as PARP inhibitors JANSSEN PHARMACEUTICA NV (BE) 2013-03-26 US disclosed
US-20100222348-A1 QUINOLINONE DERIVATIVES AS PARP INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2010-09-02 US disclosed
US-20100222348-A1 QUINOLINONE DERIVATIVES AS PARP INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2010-09-02 US disclosed
WO-2009053373-A1 QUINOLINONE DERIVATIVES AS PARP INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2009-04-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100222348-A1 QUINOLINONE DERIVATIVES AS PARP INHIBITORS PARP1, PARP2, PARP11 ALDH1A1 939/4885HIF1A 325/4885KDM4E 1008/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.